0000947871-22-000475.txt : 20220422
0000947871-22-000475.hdr.sgml : 20220422
20220422163359
ACCESSION NUMBER: 0000947871-22-000475
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220421
FILED AS OF DATE: 20220422
DATE AS OF CHANGE: 20220422
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BioLexis Pte Ltd.
CENTRAL INDEX KEY: 0001716335
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 22846034
BUSINESS ADDRESS:
STREET 1: 36 ROBINSON ROAD, #13-01 CITY HOUSE
CITY: SINGAPORE
STATE: U0
ZIP: 068877
BUSINESS PHONE: 962 6 582 7999
MAIL ADDRESS:
STREET 1: 36 ROBINSON ROAD, #13-01 CITY HOUSE
CITY: SINGAPORE
STATE: U0
ZIP: 068877
FORMER NAME:
FORMER CONFORMED NAME: GMS Tenshi Holdings Pte. Ltd
DATE OF NAME CHANGE: 20170906
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4
1
ownership.xml
X0306
4
2022-04-21
0
0001649989
Outlook Therapeutics, Inc.
OTLK
0001716335
BioLexis Pte Ltd.
36 ROBINSON ROAD, #13-06 CITY HOUSE
P.O. BOX 142904
SINGAPORE
U0
068877
SINGAPORE
0
0
1
0
Common Stock
2022-04-21
4
J
0
27982529
D
22982529
D
On April 21, 2022, the Reporting Person entered into a share purchase agreement with GMS Ventures & Investments ("GMS Ventures") pursuant to which, in connection with the transactions contemplated thereby (the "Restructuring"), GMS Ventures took direct ownership of the Issuer's shares that GMS Ventures and its affiliates (collectively, "GMS") indirectly held through its ownership in the Reporting Person. The transfer of the Issuer's shares to GMS Ventures in connection with the Restructuring occurred at the historic cost basis of GMS's investment in the Reporting Person for accounting purposes. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the price at which the transfer was effected.
GMS does not have an economic interest in, or voting rights with respect to, the shares of the Issuer held by the Reporting Person. Following the completion of the Restructuring, Tenshi Life Sciences Private Limited ("Tenshi"), a private investment vehicle controlled by Arun Kumar Pillai ("Kumar"), will become the sole shareholder of the Reporting Person. Kumar, a natural person, is the holder of a controlling interest in Tenshi. By virtue of these relationships, Kumar may be deemed to have voting and investment power with respect to the securities held by the Reporting Person and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any.
In connection with the Restructuring, the Reporting Person intends to change its name to "Tenshi Healthcare Partners".
/s/ BioLexis Pte. Ltd., By: Lawrence Kenyon, Attorney-in-Fact
2022-04-22